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MA.17 is a phase III randomised, double-blind,
placebo-controlled trial of letrozole (Femara) in post-
menopausal women with primary breast cancer, who
were disease-free after completion of 5 years (4.5–6) of
adjuvant tamoxifen. 5187 patients were randomised to
receive either oral placebo or oral letrozole 2.5 mg, daily
for 5 years. The primary endpoint was disease-free sur-
vival (DFS). Secondary endpoints included overall sur-
vival (OS), long-term safety and quality of life. Two
interim analyses were scheduled after 171 and 342
events. The protocol included strict, pre-planned stop-
ping rules; early termination had to be considered at a
nominal signiﬁcance level of P=0.0008. At the ﬁrst in-
terim analysis, which took place after a median follow-
up of 2.4 years, 132 events had occurred in the placebo
arm, 75 in the letrozole arm. The letrozole-to-placebo
hazard ratio was 0.57, with a 95% Conﬁdence Interval
(CI) of 0.43–0.75 (P=0.00008). The 4-year DFS was 93%
in the letrozole arm and 87% in the placebo arm.
This ﬁrst interim analysis with its striking results
prompted the independent data and safety monitoring
committee to recommend unblinding of the trial and to
share the results with the participants (1). Patients in the
placebo group were oﬀered to switch to letrozole.
Five years of post-operative tamoxifen therapy is still
considered the standard approach for women diagnosed
with hormone receptor (HR)-positive breast cancer (2).
So far, longer durations of adjuvant tamoxifen have not
been shown to be beneﬁcial and have been associated
with increased risks of tamoxifen-induced endometrial
cancer and thromboembolic disease (3). Another im-
portant observation is that a signiﬁcant proportion of
breast cancer recurrences (roughly 40–50%) occur more
than 5 years post-surgery (4). Taken together, these
observations provided a rationale for the assessment of
other agents with demonstrated eﬃcacy in breast cancer,
such as the aromatase inhibitors, to be tested for ex-
tended adjuvant therapy in an attempt to further im-
prove patient survival.
The eﬀectiveness of 5 years of letrozole therapy in
post-menopausal women with breast cancer who have
completed 5 years of tamoxifen therapy has been ex-
plored in this large international trial, with the en-
rolment of 5187 women (1). At the ﬁrst interim
analysis, there were 207 local or distant recurrences of
breast cancer or new primary cancers in the con-
tralateral breast – 75 in the letrozole group and 132 in
the placebo group. When analysed by site of recur-
rence, letrozole was found to be superior to placebo
and to result in fewer locoregional, but also distant
recurrences. Distant metastases are a surrogate for
survival as they almost inevitably lead to mortality.
Fewer patients in the letrozole arm (14) than in the
placebo arm (26) experienced a new primary tumour
in the contralateral breast.
At the time of analysis, a total of 42 women in the
placebo group and 31 women in the letrozole group had
died (P=0.25 for the comparison of overall survival).
Low-grade hot ﬂashes, arthritis, arthralgia, and myalgia
were more frequent in the letrozole group, but vaginal
bleeding was less frequent. There were new diagnoses of
osteoporosis (as reported by patients and unveriﬁed) in
5.8% of the women in the letrozole group and 4.5% of
the women in the placebo group (P=0.07); the rates of
fracture were similar.
Companion studies to MA.17 will be analysed: an-
nual bone mineral density (BMD) in 226 patients, lipid
proﬁles in around 320 patients, quality of life (QOL) as
assessed by Short Form (SF)-36 and the Menopause-
Speciﬁc Quality of Life (Menqol) questionnaires in ap-
proximately 3500 women.
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At this ﬁrst interim analysis, the estimated 4-year
DFS was higher in the letrozole arm (93%) than in the
placebo arm (87%), with an absolute 6% diﬀerence.
Interestingly both node-negative and node-positive
patients experienced improvement in DFS with an ab-
solute 3-year diﬀerence of 3% for node-negative and 7%
for node-positive disease. The observation that there is
increasing diﬀerence in favour of letrozole over time
suggests this diﬀerence could be even more apparent
with more prolonged follow-up, leading to a survival
diﬀerence.
Despite the short median follow-up, these results are
impressive and unlikely to be the subject of a ‘‘reversal
of fortune’’. Continued follow-up of the trial’s partici-
pants will be ensured, while women in the ‘‘control’’
group currently have the option to start letrozole ther-
apy at no cost.
This landmark trial will have a signiﬁcant impact
on endocrine adjuvant treatment strategies for the
next 10 years. In daily clinical practice, before the ﬁ-
nal results of the study are available, the decision to
oﬀer letrozole after 5 years of tamoxifen should be
individualised.
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